A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/39 (2006.01) A61K 39/04 (2006.01) A61P 31/06 (2006.01)
Patent
CA 2531825
The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium- bromide/chloride (DDA) and a lipid extract from <The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis. The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium- bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis <The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG<The present invention provides a vaccin adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium- bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from <i>Mycobacterium bovis BCG<i>. <The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from <i>Mycobacterium bovis BCG<i>. The total lipid extract contains both apolar 1ipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.
La présente invention concerne un adjuvant vaccinal composé d'un mélange d'un tensioactif, c'est-à-dire de diméthyldeoctadecylammonium-bromure/chlorure (DDA) et d'un extrait lipidique de Mycobacterium bovis BCG. L'extrait de lipides totaux contient des lipides apolaires, des lipides polaires et des lipides de polarité intermédiaire, les lipides apolaires induisant les réponses immunitaires les plus puissantes. Les lipides totaux peuvent être extraits avec du chloroforme/méthanol et à nouveau dissous dans l'eau avant l'ajout du tensioactif. Cette préparation peut être utilisée pour induire des réponses immunitaires induites par les cellules chez un mammifère, pour combattre des agents pathogènes ou comme traitement du cancer.
Agger Else Marie
Andersen Peter
Olsen Anja
Rosenkrands Ida
Ridout & Maybee Llp
Statens Serum Institut
LandOfFree
Adjuvant combinations of liposomes and mycobacterial lipids... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adjuvant combinations of liposomes and mycobacterial lipids..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant combinations of liposomes and mycobacterial lipids... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1967541